AzurRx BioPharma has expanded the ongoing Phase II RESERVOIR clinical trial of FW-1022 for the treatment of Covid-19-related gastrointestinal (GI) infections in Ukraine.

The company has concluded site initiation visits and added five new trial centres in the country.

FW-1022 is an oral tablet that consists of micronised niclosamide and is designed to carry increased concentrations of the drug directly to the GI tract.

AzurRx said that the GI tract is a likely reservoir for Covid-19 recurrence and faecal spread of SARS-CoV-2 since the entry receptor for the virus, ACE-2, is increasingly expressed on GI cells.

Niclosamide is a US Food and Drug Administration (FDA)-cleared prescription small molecule drug with anti-helminthic activity, as well as anti-inflammatory and anti-viral properties.

In April, AzurRx started the Phase II RESERVOIR trial to evaluate FW-1022 in patients with Covid-19-linked GI infection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The two-part, two-arm, placebo-controlled trial will analyse the safety of FW-1022 and its efficacy to clear the SARS-CoV-2 virus from the GI tract as primary goals.

The rate of faecal SARS-CoV-2 clearance, assessed by RT-PCR, in subjects receiving niclosamide versus placebo for up to six weeks is the trial’s primary efficacy goal.

AzurRx expects top-line results from the trial in the first quarter of next year.

Furthermore, these long-term observation data could signify the potential of niclosamide to improve symptoms of long-haul Covid-19.

AzurRx BioPharma chairman, CEO and president James Sapirstein said: “Niclosamide represents an important advance in the fight to help Covid-19 patients overcome the debilitating and often overlooked effect the virus can have on the GI system.

“The addition of new trial sites in Ukraine provides enhanced opportunity to enrol patients in a country where less than 5% of the population is fully vaccinated for Covid-19.”

Contract research organisation PPD is managing the RESERVOIR trial.

AzurRx is currently developing another micronised niclosamide formulation, FW-420, for the treatment of immune checkpoint inhibitor-associated colitis.